Companies/Pressure BioSciences, Inc.

Company profile

Pressure BioSciences, Inc.

OTC: PBIO · Healthcare · Medical - Specialties

PublicHQ Canton, MACIK 0000830656Reports USD

#791 of 1,394 Healthcare companies by revenue61st-percentile growth

EA Score

——

FH —DQ 48GM —SS 47

v0.1 · 25/100 weight · pillars only

↑ listing tenure, disclosure history · ↓ return on assets, balance-sheet leverage

Methodology →

Revenue TTM

$1.5M

Rev growth YoY (TTM)

-25.3%

Net income (FY)

-$29.3M

Employees

Market cap

$28.7k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$2.0M$2.0M2023

Net income-$29.3M-$29.3M2023

Operating income-$9.5M-$9.5M2023

Total assets$1.0M$1.0M2023

Liabilities$33.8M$33.8M2023

Equity-$32.8M-$32.8M2023

Revenue trend

FY2016 – FY2023 · USD

$2.0M

FY16

$2.2M

FY18

$2.5M

FY18

$1.8M

FY19

$1.2M

FY20

$2.0M

FY21

$1.7M

FY22

$2.0M

FY23

Revenue by segment

Filed disclosures · FY2023

By product

Hardware56%

Transferred Over At Time12%

Consumables10%

Agrochem Products9%

Sample Preparation Accessories6%

Contract Research Services4%

By geography

North America69%

Asia24%

Europe7%

The read

Pressure BioSciences, Inc. booked $2.0M in FY2023 revenue, growing 14% year over year — faster than most Healthcare companies we track, at a -1482.2% net margin.

Peers · Healthcare

Braxia Scientific Corp.——Spencer Pharmaceutical Inc.——Transnational Cannabis Ltd.——Quick-Med Technologies, Inc.——

Key facts

CEORichard T. Schumacher

SectorHealthcare

IndustryMedical - Specialties

HeadquartersCanton, MA

ExchangeOTC: PBIO

Employees16

IPO date1996-10-31

Latest filings

10-Q2025-02-07 10-Q2024-09-06 8-K2024-07-17 8-K2024-07-03 10-K2024-06-07 8-K2024-04-22 DEF 14A2024-02-27 8-K2024-01-25

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.